Castillo, F., Jones, J. D., Luba, R. R., Mogali, S., Foltin, R. W., Evans, S. M., & Comer, S. D. (2022). Gabapentin increases the abuse liability of alcohol alone and in combination with oxycodone in participants with co-occurring opioid and alcohol use disorder. Pharmacology Biochemistry and Behavior, 221, 173482. https://doi.org/10.1016/j.pbb.2022.173482

Sung, M. L., Black, A. C., Blevins, D., Henry, B. F., Cates-Wessel, K., Dawes, M. A., Drexler, K., Hagle, H., Molfenter, T., Levin, F. R., Becker, W. C., & Edelman, E. J. (2022). Adaptations to Opioid Use Disorder Care During the COVID-19 Pandemic: A National Survey of Prescribers. Journal of Addiction Medicine, 16(5), 505–513. https://doi.org/10.1097/adm.0000000000000948

Shulman, M., Hu, M. C., Nunes, E. V., & Bisaga, A. (2022). Initiating Long-acting Injectable Naltrexone: Procedure for a Second Attempt After a First Attempt Fails. Journal of Addiction Medicine, 16(5), 588–591. https://doi.org/10.1097/adm.0000000000000974

Foltin, R. W., Zale, S., Sykes, K. A., Nagaraj, N., Scranton, R. E., & Comer, S. D. (2022). A novel long-acting formulation of oral buprenorphine/naloxone produces prolonged decreases in fentanyl self-administration by rhesus monkeys. Drug and Alcohol Dependence, 239, 109599. https://doi.org/10.1016/j.drugalcdep.2022.109599

Rudolph, K. E., Williams, N. T., Goodwin, A. T. S., Shulman, M., Fishman, M., Díaz, I., Luo, S., Rotrosen, J., & Nunes, E. V. (2022). Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder. Drug and Alcohol Dependence, 239, 109609. https://doi.org/10.1016/j.drugalcdep.2022.109609

Hasin, D. S., Shmulewitz, D., Stohl, M., Greenstein, E., Aharonovich, E., Petronis, K. R., Von Korff, M., Datta, S., Sonty, N., Ross, S., Inturrisi, C., Weinberger, M. L., Scodes, J., & Wall, M. M. (2022). Diagnosing Prescription Opioid Use Disorder in Patients Using Prescribed Opioids for Chronic Pain. American Journal of Psychiatry, 179(10), 715–725. https://doi.org/10.1176/appi.ajp.21070721

Hamilton, L. K., Wheeler-Martin, K., Davis, C. S., Martins, S. S., Samples, H., & Cerdá, M. (2022). A modified Delphi process to identify experts’ perceptions of the most beneficial and harmful laws to reduce opioid-related harm. International Journal of Drug Policy, 108, 103809. https://doi.org/10.1016/j.drugpo.2022.103809

Barcelona, V., Wischik, D. L., Marshall, A., & Tetrault, J. M. (2022). Integration of medication for opioid use disorder training into graduate nursing education. Nursing Forum, 57(5), 869–873. Portico. https://doi.org/10.1111/nuf.12753

Karnik, N. S., Marsden, J., McCluskey, C., Boley, R. A., Bradley, K. A., Campbell, C. I., Curtis, M. E., Fiellin, D., Ghitza, U., Hefner, K., Hser, Y., McHugh, R. K., McPherson, S. M., Mooney, L. J., Moran, L. M., Murphy, S. M., Schwartz, R. P., Shmueli‐Blumberg, D., Shulman, M., … Wu, L. (2022). The opioid use disorder core outcomes set (OUD–COS) for treatment research: findings from a Delphi consensus study. Addiction, 117(9), 2438–2447. Portico. https://doi.org/10.1111/add.15875

Paschen-Wolff, M. M., Velasquez, R., Aydinoglo, N., & Campbell, A. N. C. (2022). Simulating the experience of searching for LGBTQ-specific opioid use disorder treatment in the United States. Journal of Substance Abuse Treatment, 140, 108828. https://doi.org/10.1016/j.jsat.2022.108828

Greiner, M. G., Shulman, M., Scodes, J., Choo, T.-H., Pavlicova, M., Opara, O., Campbell, A. N. C., Novo, P., Fishman, M., Lee, J. D., Rotrosen, J., & Nunes, E. V. (2022). Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone. Substance Use & Misuse, 57(11), 1732–1742. https://doi.org/10.1080/10826084.2022.2112230

Jones, J. D., Campbell, A. N., Brandt, L., Metz, V. E., Martinez, S., Wall, M., Corbeil, T., Andrews, H., Castillo, F., Neale, J., Strang, J., Ross, S., & Comer, S. D. (2022). A randomized clinical trial of the effects of brief versus extended opioid overdose education on naloxone utilization outcomes by individuals with opioid use disorder. Drug and Alcohol Dependence, 237, 109505. https://doi.org/10.1016/j.drugalcdep.2022.109505

Williams, A. R., Mauro, C. M., Feng, T., Wilson, A., Cruz, A., Olfson, M., Crystal, S., Samples, H., & Chiodo, L. (2022). Non–prescribed buprenorphine preceding treatment intake and clinical outcomes for opioid use disorder. Journal of Substance Abuse Treatment, 139, 108770. https://doi.org/10.1016/j.jsat.2022.108770

Samples, H., Williams, A. R., Crystal, S., & Olfson, M. (2022). Psychosocial and behavioral therapy in conjunction with medication for opioid use disorder: Patterns, predictors, and association with buprenorphine treatment outcomes. Journal of Substance Abuse Treatment, 139, 108774. https://doi.org/10.1016/j.jsat.2022.108774

Beauchemin, M. P., Raghunathan, R. R., Accordino, M. K., Cogan, J. C., Kahn, J. M., Wright, J. D., & Hershman, D. L. (2022). New persistent opioid use among adolescents and young adults with sarcoma. Cancer, 128(14), 2777–2785. Portico. https://doi.org/10.1002/cncr.34238

Tsui, J. I., Campbell, A. N. C., Pavlicova, M., Choo, T.-H., Lee, J. D., Cook, R. R., Shulman, M., Nunes, E. V., & Rotrosen, J. (2022). Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone. Drug and Alcohol Dependence, 236, 109469. https://doi.org/10.1016/j.drugalcdep.2022.109469

Nesoff, E. D., Marziali, M. E., & Martins, S. S. (2021). The estimated impact of state‐level support for expanded delivery of substance use disorder treatment during the COVID‐19 pandemic. Addiction, 117(6), 1781–1786. Portico. https://doi.org/10.1111/add.15778

Kluger, M. D., Huang, Y. Y., Kuo, J. H., Kwon, W., Thomas, A. S., Hershman, D. L., Schrope, B. A., Sugahara, K. N., Chabot, J. A., & Wright, J. D. (2022). Perioperative and persistent opioid utilization following pancreatectomy in the United States. HPB, 24(6), 912–924. https://doi.org/10.1016/j.hpb.2021.10.021

Mintz, C. M., Xu, K. Y., Presnall, N. J., Hartz, S. M., Levin, F. R., Scherrer, J. F., Bierut, L. J., & Grucza, R. A. (2022). Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder. JAMA Network Open, 5(5), e2211634. https://doi.org/10.1001/jamanetworkopen.2022.11634

Na, P. J., Scodes, J., Fishman, M., Rotrosen, J., & Jr, E. V. N. (2022). Co-occurring Depression and Suicidal Ideation in Opioid Use Disorder. The Journal of Clinical Psychiatry, 83(3). https://doi.org/10.4088/jcp.21m14140

McNeely, J., Schatz, D., Olfson, M., Appleton, N., & Williams, A. R. (2022). How Physician Workforce Shortages Are Hampering the Response to the Opioid Crisis. Psychiatric Services, 73(5), 547–554. https://doi.org/10.1176/appi.ps.202000565

Shulman, M., Hu, M.-C., Sullivan, M. A., Akerman, S. C., Fratantonio, J., Barbieri, V., Nunes, E. V., & Bisaga, A. (2022). Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials. Drug and Alcohol Dependence, 233, 109343. https://doi.org/10.1016/j.drugalcdep.2022.109343

Blevins, D., Henry, B. F., Sung, M., Edelman, E. J., Black, A. C., Dawes, M., Molfenter, T., Hagle, H., Drexler, K., Cates-Wessel, K., & Levin, F. R. (2022). Well-Being of Health Care Professionals Treating Opioid Use Disorder During the COVID-19 Pandemic: Results From a National Survey. Psychiatric Services, 73(4), 374–380. https://doi.org/10.1176/appi.ps.202100080

Tookes, H., Ucha, J., Rodriguez, A. E., Suarez, E., Alonso, E., Metsch, L. R., Feaster, D. J., Bartholomew, T. S., Hoffman, K. A., & Korthuis, P. T. (2021). Recruitment into a Clinical Trial of People Living with Uncontrolled HIV Infection Who Inject Drugs: a Site Case Report from the CTN 67 CHOICES Study. The Journal of Behavioral Health Services & Research, 49(2), 240–251. https://doi.org/10.1007/s11414-021-09771-3

Mauro, P. M., Gutkind, S., Annunziato, E. M., & Samples, H. (2022). Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019. JAMA Network Open, 5(3), e223821. https://doi.org/10.1001/jamanetworkopen.2022.3821

Evangelidis‐Sakellson, V., & Rifkin, M. (2021). Effectiveness of online training of first and second year AEGD residents in identifying, referring, and managing patients at‐risk for substance use and opioid disorders. Journal of Dental Education, 86(3), 319–327. Portico. https://doi.org/10.1002/jdd.12795

Streck, J. M., Parker, M. A., Bearnot, B., Kalagher, K., Sigmon, S. C., Goodwin, R. D., & Weinberger, A. H. (2022). National Trends in Suicide Thoughts and Behavior among US Adults with Opioid Use Disorder from 2015 to 2020. Substance Use & Misuse, 57(6), 876–885. https://doi.org/10.1080/10826084.2022.2046102

Crystal, S., Nowels, M., Samples, H., Olfson, M., Williams, A. R., & Treitler, P. (2022). Opioid overdose survivors: Medications for opioid use disorder and risk of repeat overdose in Medicaid patients. Drug and Alcohol Dependence, 232, 109269. https://doi.org/10.1016/j.drugalcdep.2022.109269

Wang, A., Shulman, M., Choo, T., Pavlicova, M., Langleben, D. D., Nunes, E. V., & Rotrosen, J. (2021). Baseline‐ and treatment‐associated pain in the X:BOT comparative effectiveness study of extended‐release naltrexone versus buprenorphine‐naloxone for OUD. Addiction Biology, 27(2). Portico. https://doi.org/10.1111/adb.13112

Rudolph, K. E., Shulman, M., Fishman, M., Díaz, I., Rotrosen, J., & Nunes, E. V. (2021). Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse. Addiction, 117(3), 637–645. Portico. https://doi.org/10.1111/add.15654

Roache, J. D., Pavlicova, M., Campbell, A., Choo, T., Peavy, M., Kermack, A. S., Nunes, E. V., & Rotrosen, J. (2021). Is extended release naltrexone superior to buprenorphine‐naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial. Alcoholism: Clinical and Experimental Research, 45(12), 2569–2578. Portico. https://doi.org/10.1111/acer.14729

Rudolph, K. E., Díaz, I., Luo, S. X., Rotrosen, J., & Nunes, E. V. (2021). Optimizing opioid use disorder treatment with naltrexone or buprenorphine. Drug and Alcohol Dependence, 228, 109031. https://doi.org/10.1016/j.drugalcdep.2021.109031

Behrends, C. N., Gutkind, S., Winkelstein, E., Wright, M., Dolatshahi, J., Welch, A., Paone, D., Kunins, H. V., & Schackman, B. R. (2022). Costs of Opioid Overdose Education and Naloxone Distribution in New York City. Substance Abuse, 43(1), 692–698. https://doi.org/10.1080/08897077.2021.1986877

Rabinowitz, L. G., Zylberberg, H. M., Yang, J., Gold, S. L., Chesner, J., Ji, J., Hu, L., & Dubinsky, M. (2021). De Novo Ostomy Placement Is Associated with Increased Outpatient Opioid Use In Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 67(8), 4033–4042. https://doi.org/10.1007/s10620-021-07257-y

Joudrey, P. J., Bart, G., Brooner, R. K., Brown, L., Dickson-Gomez, J., Gordon, A., Kawasaki, S. S., Liebschutz, J. M., Nunes, E., McCarty, D., Schwartz, R. P., Szapocnik, J., Trivedi, M., Tsui, J. I., Williams, A., Wu, L.-T., & Fiellin, D. A. (2021). Article Commentary: Research Priorities for Expanding access to Methadone Treatment for Opioid use Disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force Report. Substance Abuse, 42(3), 245–254. https://doi.org/10.1080/08897077.2021.1975344

Brandt, L., Campbell, A. N. C., Jones, J. D., Martinez, S., Neale, J., Parkin, S., Brown, C., Strang, J., & Comer, S. D. (2022). Emotional Reactions of Trained Overdose Responders who use Opioids following Intervention in an Overdose Event. Substance Abuse, 43(1), 581–591. https://doi.org/10.1080/08897077.2021.1975870